News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
258,833 Results
Type
Article (13482)
Company Profile (103)
Press Release (245248)
Section
Business (87815)
Career Advice (460)
Deals (15316)
Drug Delivery (60)
Drug Development (36461)
Employer Resources (49)
FDA (6230)
Job Trends (6178)
News (149716)
Policy (13991)
Tag
Academia (435)
Africa (312)
Alliances (23034)
Alzheimer's disease (322)
Approvals (6213)
Arizona (35)
Artificial intelligence (39)
Asia (19628)
Australia (2531)
Bankruptcy (143)
Best Places to Work (4196)
Biosimilars (31)
Biotechnology (41)
C2C Services and Suppliers (10601)
California (580)
Canada (425)
Cancer (124)
Career advice (402)
Cell therapy (23)
China (63)
Clinical research (30025)
Collaboration (49)
Compensation (23)
Connecticut (24)
COVID-19 (735)
Cystic fibrosis (21)
Data (82)
Diabetes (25)
Diagnostics (1200)
Drug pricing (47)
Earnings (31137)
Employer resources (43)
Europe (38373)
Events (36243)
Executive appointments (78)
FDA (6293)
Florida (73)
Funding (36)
Gene therapy (40)
GLP-1 (259)
Government (1248)
Healthcare (3502)
Hotbed/Location (177916)
Illinois (67)
Indiana (57)
Infectious disease (739)
Inflammatory bowel disease (40)
Interviews (57)
IPO (5780)
IRA (22)
Job creations (2046)
Job search strategy (371)
Kansas (49)
Layoffs (164)
Legal (3398)
Lung cancer (27)
Manufacturing (43)
Maryland (84)
Massachusetts (512)
Medical device (1251)
Medtech (1253)
Mergers & acquisitions (9472)
Metabolic disorders (99)
Minnesota (36)
Neuroscience (371)
New Jersey (237)
New York (162)
NextGen Class of 2024 (1576)
Non-profit (588)
North Carolina (221)
Northern California (258)
Obesity (60)
Ohio (28)
Opinion (106)
Patents (39)
Pennsylvania (183)
People (28217)
Pharmaceutical (59)
Phase I (7818)
Phase II (12692)
Phase III (11401)
Pipeline (48)
Podcasts (35)
Policy (35)
Postmarket research (1398)
Preclinical (3127)
Press Release (25)
Rare diseases (50)
Real estate (2624)
Regulatory (9687)
Research institute (561)
Resumes & cover letters (55)
South America (496)
Southern California (259)
Startups (1623)
Texas (75)
United States (2576)
Vaccines (89)
Washington State (46)
Weight loss (52)
Date
Today (41)
Last 7 days (215)
Last 30 days (780)
Last 365 days (13329)
2024 (9190)
2023 (14244)
2022 (19556)
2021 (20068)
2020 (19033)
2019 (14886)
2018 (11713)
2017 (13891)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
258,833 Results for "venatorx pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Venatorx Pharmaceuticals Announces Changes to Executive Leadership
Venatorx Pharmaceuticals announced today several changes to its executive leadership team.
May 16, 2024
·
4 min read
Business
Venatorx Pharmaceuticals Expands Senior Leadership Team
Venatorx Pharmaceuticals announced expansion of its leadership team with three key industry veterans: Jason Burdette joining as Senior Vice President, CMC and Technical Operations: Armand Girard as Chief Business Officer; and Tamra Adams, and Chief Financial Officer.
March 12, 2024
·
4 min read
Pharm Country
Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam
Venatorx Pharmaceuticals (Venatorx) and Melinta Therapeutics (Melinta) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for cefepime-taniborbactam.
February 23, 2024
·
12 min read
Business
Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries
Venatorx Pharmaceuticals and Menarini Group today announced that they have entered into an agreement under which Menarini will acquire the exclusive rights to commercialize, upon approval of relevant health authorities, cefepime-taniborbactam in 96 countries.
January 9, 2024
·
6 min read
Pharm Country
Venatorx Pharmaceuticals to Present at IDWeek 2023
Venatorx Pharmaceuticals today announced seven presentations during IDWeek 2023, October 11-15, 2023, in Boston, MA.
September 27, 2023
·
8 min read
Drug Development
Everest Medicines’ Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam’s Phase 3 CERTAIN-1 Study in New England Journal of Medicine
Everest Medicines ‘s licensing partner, Venatorx Pharmaceuticals announced that The New England Journal of Medicine published the results of the CERTAIN-1 Phase 3 clinical study of the investigational agent cefepime-taniborbactam for the treatment of adult patients with complicated urinary tract infections, including acute pyelonephritis.
February 20, 2024
·
6 min read
Business
Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract
Venatorx Pharmaceuticals today announced the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), has awarded the company a contract to support the development of oral ceftibuten-ledaborbactam etzadroxil for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.
October 10, 2023
·
8 min read
Pharm Country
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.
Melinta Therapeutics LLC and Venatorx Pharmaceuticals, Inc., announced that they have entered into a License Agreement to facilitate a strategic partnership in the U.S. to commercialize cefepime-taniborbactam, a beta-lactam / beta-lactamase inhibitor combination antibiotic being developed for the treatment of complicated urinary tract infections and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adults.
November 9, 2023
·
13 min read
Pharm Country
Venatorx Pharmaceuticals Highlights Two Recent Publications Indicating Rising Metallo-Beta-Lactamases for Carbapenem-Resistant Enterobacterales in US
Venatorx Pharmaceuticals today highlights two recent publications that provide important updates on the changing epidemiology of carbapenem-resistant Enterobacterales (CRE) globally and in the United States (US).
August 14, 2023
·
8 min read
Business
Venatorx Pharmaceuticals Appoints Tomas J. Heyman as Non-Executive Chairman
Venatorx Pharmaceuticals today announced changes to its Board of Directors.
March 7, 2023
·
4 min read
1 of 25,884
Next